人纤维蛋白原对急诊外伤致创伤性凝血病疗效及相关因素分析

doi:10.12092/j.issn.1009-2501.2019.06.015

摘要/Abstract

摘要：

目的:探讨人纤维蛋白原(fibrinogen，FIB)对急诊创伤性凝血病患者的临床疗效及相关因素。方法:将2015年6月至2018年6月本院收治的100例严重创伤患者纳入本研究，根据是否创伤性凝血病分为凝血病组(80例)和非凝血病组(20例)。比较凝血病组和非凝血病组患者收住后第1个24 h的急性生理和慢性健康评分(acute physiology and chronic health evaluation II，APACHE II)、创伤严重程度评分(injury severity score，ISS)、低体温及低灌注发生率等指标。采用Logistic多因素回归方法分析严重创伤患者发生创伤性凝血病的相关因素。将80例创伤性凝血病患者随机分为观察组(40例)和对照组(40例)。对照组按照常规诊疗措施治疗，观察组在对照组处理基础上给予人FIB，比较治疗前后观察组和对照组的凝血功能指标，及治疗后的临床用血量、住院时间及病死率。结果:与治疗前相比，治疗后观察组和对照组的凝血酶原时间(prothrombin time，PT)、活化部分凝血活酶时间(activated partial thromboplastin time，APTT)及D-二聚体水平降低(P<0.05)，FIB水平明显升高(P<0.05)。观察组的红细胞(red blood cell，RBC) 输注量、新鲜冰冻血浆(fresh frozen plasma，FFP)输注量、重症加强护理病房(intensive care unit，ICU)时间及病死率均明显低于对照组，差异具有统计学意义(P<0.05)。创伤性凝血病患者PT>18 s(r=0.623，P=0.024)、APTT>60 s(r=0.722，P=0.018)、凝血酶时间(thrombin time，TT)>15 s(r=0.719，P=0.033)与ISS评分呈正相关。碱缺失(base deficit，BD)≥6(OR=3.678，95%CI=1.065～9.417)、格拉斯哥评分(Glasgow coma scale，GCS)≤8(OR=5.299，95%CI=1.122～8.711)和血小板(platelet，PLT)计数(OR=0.982，95%CI=0.971～0.996)是严重创伤患者发生创伤性凝血病的独立预测因素。结论:人FIB可有效改善创伤性凝血病患者的凝血功能，降低病死率、缩短ICU时间，创伤性凝血病与创伤严重程度、合并休克、低体温和重型颅脑损伤存在一定的相关性。

关键词: 纤维蛋白原, 创伤性凝血病, 凝血功能, 疗效, 相关因素

Abstract:

AIM:To investigate the clinical efficacy of human fibrinogen(FIB) in patients with emergency traumatic coagulopathy and the related factors in patients with traumatic coagulopathy. METHODS:One hundred patients with severe trauma admitted to our hospital from June 2015 to June 2018 were included in the study. According to whether the traumatic coagulopathy，they were classified into coagulopathy group (80 cases) and non-coagulopathy group (20 cases). The acute physiology and chronic health evaluation II (APACHE II) and the injury severity score (ISS) of the first 24 h after admission，hypothermia and hypoperfusion incidence were compared between the patients in the coagulopathy group and the non-coagulopathy group. Logistic multivariate regression analysis was used to analyze the related factors of traumatic coagulopathy in patients with severe trauma. Eighty patients with traumatic coagulopathy were randomly divided into observation group (40 cases) and control group (40 cases). The control group was given conventional medical treatment. The observation group was given human fibrinogen based on the control group. The coagulation function indexes and the clinical blood volume，hospitalization time and mortality of of the observation group and the control group were compared.RESULTS:Compared with before treatment，the prothrombin time (PT)，activated partial thromboplastin time (APTT) and D-dimer levels were decreased，the level of fibrinogen (FIB) was significantly increased in the observation group and the control group after treatment(P<0.05). The red blood cell(RBC) infusion volume，fresh frozen plasma(FFP) infusion volume，intensive care unit(ICU) time and mortality rate of the observation group were significantly lower than those in the control group(P<0.05).Traumatic coagulation patients with PT>18 s (r=0.623，P=0.024)，APTT>60 s (r=0.722，P=0.018)，thrombin time(TT>15 s (r=0.719，P=0.033) were positively correlated with ISS scores. Base deficit(BD)≥6 (OR=3.678，95%CI=1.065-9.417)，Glasgow coma scale(GCS)≤8 (OR=5.299，95%CI=1.122-8.711) and platelet(PLT) count (OR=0.982，95%CI=0.971-0.996) were the independent predictors of traumatic coagulopathy in patients with severe trauma.CONCLUSION:Human FIB can effectively improve the coagulation function of patients with traumatic coagulopathy，reduce the mortality rate，shorten the ICU time，and there is certain correlation between traumatic coagulopathy and trauma severity，combined with shock，hypothermia and severe craniocerebral injury.

Key words: fibrinogen, traumatic coagulopathy, coagulation, efficacy, related factors

中图分类号:

R651.1

朱悚之. 人纤维蛋白原对急诊外伤致创伤性凝血病疗效及相关因素分析[J]. 中国临床药理学与治疗学, 2019, 24(6): 693-698.

ZHU Songzhi. Therapeutic effect and related factors of human fibrinogen on traumatic traumatic coagulopathy[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(6): 693-698.

参考文献

［1］李波,赵智刚,唐忠志.严重创伤合并创伤性凝血病的临床治疗分析［J］.临床外科杂志,2016,14(4):302-304.
［2］Grace M，Dhavan S，Nora E，et al.Relationship of coagulopathy and platelet dysfunction to transfusion needs after traumatic brain injury［J］.Neurocrit Care,2018,28(3):330-337.
［3］梅程清,叶正龙,邹晖，等.多发伤患者创伤性凝血病影响因素分析［J］.中国医刊,2017,22(12):85-88.
［4］姜亚静,侯军林.创伤性凝血病的早期诊断［J］.现代仪器与医疗,2018,43(1):79-81.
［5］White NJ, Newton JC, Martin EJ，et al.Clot formation is associated with fibrinogen and platelet forces in a cohort of severely injured emergency department trauma patients［J］.Shock,2015，44 (Suppl 1):39-44.
［6］周跃,顾怀金.早期止凝血管理治疗创伤性凝血病的疗效研究［J］.临床输血与检验,2016,21(5):455-458.
［7］Ross Davenport.Coagulopathy following major trauma hemorrhage: lytic，lethal and a lack of fibrinogen［J］.Crit Care，2014,18(6):151.
［8］张静,思永玉.创伤性凝血病的研究进展［J］.麻醉安全与质控,2018,33(3):174-180.
［9］刘月高.急性创伤性凝血病的最新研究进展［J］.中国急救医学,2016,8(2):186-190.
［10］Panel SL, Schreiber M, Cohen M，et al.Coagulopathy after head injury: uncommon by conventional coagulation testing and associated with platelet-fibrinogen dysfunction［J］.J Surg Res,2013,179(2):272-273.
［11］陈鑫,李亮,杨志洲，等.D-二聚体联合损伤严重度评分对创伤患者预后的预测价值［J］.中华急诊医学杂志,2018,13(5):486-491.
［12］赵剑斓,袁强,吴惺，等.凝血指标对于颅脑创伤患者住院病死率的预测价值［J］.中华神经外科杂志,2018,22(2):134-138.
［13］Sillesen M, Johansson PI, Rasmussen LS,et al.Platelet activation and dysfunction in a large-animal model of traumatic brain injury and hemorrhage［J］.J Trauma Acute Care,2013,74(5):1252-1259.
［14］Monisha A，Kuma.Coagulopathy associated with traumatic brain injury［J］.Curr Neurol Neurosci,2013,13(9):391.
［15］血凝酶在急性出血临床应用专家组.血凝酶在急性出血性疾病中应用的专家共识［J］.中华急诊医学杂志,2018,11(2):137-140.

[1]	许宜琪, 吴茜, 刘书, 刘帆, 邢春燕, 李勤, 何俊俊, 何春玲, 赵咏莉, 高家林. 雷公藤多苷治疗糖尿病肾脏病的临床疗效及抗炎抗纤维化分析[J]. 中国临床药理学与治疗学, 2023, 28(9): 1034-1042.
[2]	肖悦, 李唐菲, 薛乾富. 聚乙二醇干扰素-α治疗原发性血小板增多症的疗效和安全性分析[J]. 中国临床药理学与治疗学, 2023, 28(9): 1049-1055.
[3]	陶言言, 汤亚杰, 王丽丽, 王方莉, 陆国玉, 范方田. 皖北地区抗凝类杀鼠剂中毒临床特征及维生素K1用药方案对疗效的影响分析[J]. 中国临床药理学与治疗学, 2023, 28(11): 1263-1268.
[4]	黄小明, 杜野, 林少明, 沈观乐. 呼吸道微生态对晚期非小细胞肺癌患者接受PD-1抑制剂单药治疗疗效影响的探索性研究[J]. 中国临床药理学与治疗学, 2023, 28(1): 66-74.
[5]	晏玉奎, 胡建琴, 张冰. 新型和传统抗癫痫药物治疗新诊断部分性癫痫的临床研究[J]. 中国临床药理学与治疗学, 2022, 27(7): 793-799.
[6]	鲍静, 陈晓文, 夏亮, 赵雨辰, 夏瑞祥, 夏海龙. 伊沙佐米治疗多发性骨髓瘤的临床疗效和安全性分析[J]. 中国临床药理学与治疗学, 2021, 26(7): 782-786.
[7]	黄伊婷, 沈爱宗. 阿法替尼治疗肺癌的临床疗效与安全性[J]. 中国临床药理学与治疗学, 2021, 26(4): 474-480.
[8]	李静, 马丽娟, 袁圆, 王捷, 郁长治, 赵军. 吸入性糖皮质激素布地奈德相关基因多态性与哮喘疗效的关系[J]. 中国临床药理学与治疗学, 2021, 26(11): 1250-1258.
[9]	林荣芳, 郑玮玮, 刘亦伟, 林翠鸿, 王长连, 黄品芳. 克罗恩病患者英夫利西单抗相关基因多态性与血药浓度及疗效关联性研究[J]. 中国临床药理学与治疗学, 2020, 25(9): 1000-1006.
[10]	赵倩，杨广，曹莉华，于陈宝. CNR1基因遗传变异对利拉鲁肽治疗早期2型糖尿病患者临床疗效的影响[J]. 中国临床药理学与治疗学, 2020, 25(2): 182-188.
[11]	石莉莉, 刘兴安, 单国用. 阿帕替尼后线治疗标准方案失败的晚期结直肠癌的疗效和安全性及疗效预测因子的初步分析[J]. 中国临床药理学与治疗学, 2020, 25(12): 1388-1394.
[12]	闫盼, 施剑飞, 李静, 王晟东, 王姝琪, 汪程鹏, 宋明芬. DRD2和5-HTR2A基因多态性及其交互作用对奥氮平治疗精神分裂症疗效的影响[J]. 中国临床药理学与治疗学, 2020, 25(10): 1131-1138.
[13]	尹子毅，王峰，赵梦，张铁，王丕琳. 卡培他滨为基础一线方案治疗Her2阴性转移性乳腺癌的单中心回顾性研究及TYMP基因多态性分析[J]. 中国临床药理学与治疗学, 2019, 24(9): 1002-1008.
[14]	林敏，沈仲夏，钱敏才，崔力军，任列，蔡敏，沈鑫华. 5-羟色胺转运体基因多态性与抗抑郁剂治疗广泛性焦虑障碍疗效的关联[J]. 中国临床药理学与治疗学, 2019, 24(8): 903-909.
[15]	郭良堂，林超，孙云，戴盛锋，张炳才，陈舒. 二甲双胍对多囊卵巢综合征患者疗效及其对患者脂肪组织miR-25水平的影响[J]. 中国临床药理学与治疗学, 2019, 24(5): 554-560.